4//SEC Filing
Nunn Jason Raleigh 4
Accession 0000950170-24-106979
CIK 0001953926other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 8:54 PM ET
Size
17.8 KB
Accession
0000950170-24-106979
Insider Transaction Report
Form 4
Nunn Jason Raleigh
Director
Transactions
- Conversion
Common Stock
2024-09-16+1,505,388→ 1,505,388 total(indirect: See Note 2) - Conversion
Series C Convertible Preferred Stock
2024-09-16−5,809,528→ 0 total(indirect: See Note 3)→ Common Stock (669,061 underlying) - Purchase
Common Stock
2024-09-16$17.00/sh+441,176$7,499,992→ 1,110,237 total(indirect: See Note 3) - Conversion
Common Stock
2024-09-16+669,061→ 669,061 total(indirect: See Note 3) - Purchase
Common Stock
2024-09-16$17.00/sh+441,176$7,499,992→ 1,946,564 total(indirect: See Note 2) - Conversion
Series C Convertible Preferred Stock
2024-09-16−13,071,439→ 0 total(indirect: See Note 2)→ Common Stock (1,505,388 underlying) - Award
Stock Option (Right to Buy)
2024-09-12+37,000→ 37,000 totalExercise: $17.00Exp: 2034-09-11→ Common Stock (37,000 underlying)
Footnotes (4)
- [F1]On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]The reported securities are held directly by SR One Capital Fund II Aggregator, LP. SR One Capital Partners II, LP is the general partner of SR One Capital Fund II Aggregator, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Fund II Aggregator, LP, and a limited partner of SR One Capital Partners II, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
- [F3]The reported securities are held directly by SR One Capital Opportunities Fund I, LP. SR One Capital Opportunities Partners I, LP is the general partner of SR One Capital Opportunities Fund I, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Opportunities Fund I, LP, and a limited partner of SR One Capital Opportunities Partners I, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
- [F4]The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service.
Documents
Issuer
Zenas BioPharma, Inc.
CIK 0001953926
Entity typeother
Related Parties
1- filerCIK 0001444319
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 8:54 PM ET
- Size
- 17.8 KB